CD4 and infection: Although the vaccine did not protect in either trial (0-6% vaccine efficacy), post-trial analyses of serum samples from the Vax004 cohort showed that Ab reactivity with the CD4-binding site (CD4bs) on gp120, as well as antibody-dependent cell-mediated viral inhibition (ADCVI), correlated inversely with the risk of infection [3,21].